References
  1. Melmed S. Physiology of growth hormone. UpToDate. In: Rose BD, editor. UpToDate. 2008. Waltham, MA.
  2. Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications. Nature reviews Endocrinology. 2010;6(9):515–25.
  3. FDA. FDA Drug Safety Podcast for Healthcare Professionals: Ongoing safety review of Recombinant Human Growth Hormone (somatropin) and possible increased risk of death.
  4. Plotkin D, Ng J, Farmer M, Gelato M, Kaiser F, Kiel D, Korenman S, McKeever C, Munoz, Schwartz R, Krupa D, Gormley G, Bach MA. Use of MK-677, an oral GH secretagogue in frail elderly subjects. Endocrinol Metab 1997;4(SupplA):35–36.
  5. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002;288:2282–92.
  6. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
  7. Del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA, et al. Growth hormone regulation of p85 alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 2007;56:1638–46.
  8. Turżańska K, Drelich M, Posturzyńska A. Protein and physical activity in prevention and treatment of sarcopenia. Wiad Lek. 2019;72(9 cz 1):1660-1666.
  9. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med . 2008;149(9):601–611. doi:10.7326/0003-4819-149-9-200811040-00003.
  10. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018 Jan;6(1):45-53. doi: 10.1016/j.sxmr.2017.02.004. Epub 2017 Apr 8.
  11. Campbell GA, Patrie JT, Gaylinn BD, Thorner MO, Bolton WK. Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study. Nephrol Dial Transplant. 2018 Mar 1;33(3):523-530. doi: 10.1093/ndt/gfw474.
  12. Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011 Sep-Oct;53(2):183-9. doi: 10.1016/j.archger.2010.10.004. Epub 2010 Nov 9.
  13. Bach MA, Rockwood K, Zetterberg C, Thamsborg G, Hébert R, Devogelaer JP, Christiansen JS, Rizzoli R, Ochsner JL, Beisaw N, Gluck O, Yu L, Schwab T, Farrington J, Taylor AM, Ng J, Fuh V; MK 0677 Hip Fracture Study Group. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc. 2004 Apr;52(4):516-23.
  14. Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Miner Res. 1999 Jul;14(7):1182-8.
  15. Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. The Journal of clinical endocrinology and metabolism. 1996;81(12):4249–57.